Remicade Supply Chain Changes Among J&J’s International Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Xarelto and Invokana growth are highlights of J&J’s first quarter; Zytiga’s sales are a bright spot too – even if its market share isn’t.